A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). (January 2016)

• Record Type: Journal Article
• Authors: Tryfonidis, Konstantinos; Basaran, Gul; Bogaerts, Jan; Debled, Marc; Dirix, Luc; Thery, Jean-Christophe; Tjan-Heijnen, Vivianne C.G.; Van den Weyngaert, Danielle; Cufer, Tanja; Piccart, Martine; Cameron, David
• Is Part Of: European journal of cancer. Volume 53(2016)
• Page Start: 144
• Page End: 154
• Publication Date: 2016-01
• Subjects: Anastrozole -- Gefitinib -- Metastatic breast cancer -- Endocrine resistance; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.10.012
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. gefitinib) can delay endocrine resistance in breast cancer. A double-blind, placebo-controlled, phase II trial investigated whether adding gefitinib (G) to anastrozole (A) would improve outcome in advanced breast cancer (ABC). Methods: Postmenopausal pre-treated hormone receptor-positive ABC patients (locally recurrent or metastatic) were 1:1 randomized to A (1 mg/d) plus G 250 mg/d or plus placebo (P). Patients who had prior treatment with an aromatase inhibitor in metastatic setting or with trastuzumab, anti-EGFR or anti-VEGF agents were excluded. Treatment was given until disease progression, unacceptable toxicity or patient withdrawal. Progression-free survival (PFS) rate at 1 year was assessed according to Response Evaluation Criteria in Solid Tumours, version 1.0. Results: Of 108 planned patients, 71 were recruited (36 in A/G and 35 in A/P). The trial closed prematurely due to slow recruitment; 31 patients had prior chemotherapy and 53 prior endocrine therapy (all except one received tamoxifen); 60% in adjuvant and 16% in metastatic setting received tamoxifen; 59 patients had visceral disease. Median follow-up was 18 months. PFS rate at 1 year was 35% for A/G and 32% for A/P arm. Objective responses were six (22%) in the A/G and nine (28%) in the A/P arm. Median duration of response was 13.8 and 18.6 months in the A/G and A/P arms, respectively. Fatigue (35%), diarrhoea (31%), rash (32%), dry skin (27%), and arthralgia/myalgia (27%) were the commonest adverse events in the A/G arm. Conclusions: This phase II study, although prematurely closed, did not show a signal that adding G to A improves PFS at 1 year and its use is not supported. Gastrointestinal and skin toxicities were more pronounced with G resulting in premature therapy interruption in almost 1 in 3 patients (ClinicalTrials.gov number, NCT00066378 ). Highlights: Epidermal growth factor receptor inhibitors are believed to overcome/delay breast cancer endocrine resistance. Hormone receptor-positive metastatic women were randomized to anastrozole (A) and gefitinib (G) or placebo (P). 1-Year progression-free survival rate was 35% for A/G and 32% for A/P. One-third of G arm patients stopped treatment due to intestinal and skin toxicities. Results do not support endocrine resistance delay by adding G to A.